J9176
J9176 – Injection, elotuzumab, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 1 MG $8.189/unit ASP+6%
📋 J9176 summary
J9176 is a HCPCS Level II J-code used to bill elotuzumab, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9176: Empliciti
Code J9176
Billing unit 1 MG Payment limit $8.189/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9176
DescriptorInjection, elotuzumab, 1 mg
Billing unit1 MG
Payment limit / unit$8.189
Est. ASP / unit$7.725 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
💊 About Elotuzumab Injection DRUG GUIDE
Empliciti is used to treat multiple myeloma (a cancer of plasma cells in the bone marrow) in adults who have already tried other treatments.
It is always given as part of a combination regimen — never alone.Empliciti combined with lenalidomide and dexamethasone is used in adults who have received one to three prior therapies.
Empliciti combined with pomalidomide and dexamethasone is used in adults who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Clinical overview from our editorial drug guide for Elotuzumab Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$8.189
Est. ASP / unit
$7.725 est.
Est. after 2% sequester
$8.025
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, elotuzumab, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2017-01-01
Date added2017-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9176 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9176 WITH EST. MEDICARE PAY
2 NDCs map to J9176. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($8.189/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00003-2291-11 | EMPLICITI elotuzumab 300 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | E.R. | 1 VIAL, SINGLE-USE in 1 CARTON (0003-2291-... | 300 mg/1 | 300 | $2,456.70 | — | ● Active | CMS ASP |
| 00003-4522-11 | EMPLICITI elotuzumab 400 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | E.R. | 1 VIAL, SINGLE-USE in 1 CARTON (0003-4522-... | 400 mg/1 | 400 | $3,275.60 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$17.91M
Claims
1,951
Beneficiaries
587
Spend / beneficiary
$30,518.24
Spend / claim
$9,182.06
Trend by period
Where J9176 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #131 of 824
#126
POTELIGEO J9204
$20.58M
#127
COLUMVI J9286
$20.19M
#128
IHEEZO J2403
$19.59M
#129
NEXVIAZYME J0219
$18.44M
#130
AMCHOPLAST, PER SQ C... Q4316
$18.44M
#131
EMPLICITI J9176
$17.91M
#132
DALBAVANCIN HCL* J0875
$17.7M
#133
ELREXFIO J1323
$16.82M
#134
ALYMSYS Q5126
$16.72M
#135
IDELVION J7202
$16.67M
#136
NIKTIMVO J9038
$16.36M
Total claims — #319 of 824
#314
NYVEPRIA Q5122
2,011
#315
HERCEPTIN HYLECTA J9356
2,001
#316
GLASSIA J0257
1,989
#317
SOLIRIS(J1299) J1299
1,976
#318
HERZUMA Q5113
1,968
#319
EMPLICITI J9176
1,951
#320
TOBRAMYCIN SULFATE J3260
1,945
#321
DILAUDID* J1171
1,926
#322
INVEGA SUSTENNA J2426
1,926
#323
ALBUTEROL SULFATE(J7... J7611
1,926
#324
VINCASAR PFS* J9370
1,920
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $17.91M | 587 | 1,951 | $30,518.24 | $9,182.06 |
| 2025 (Q1-Q4) | $77.84M | 1,038 | 8,832 | $74,988.99 | $8,813.24 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$28.96M
Medicare paid
$22.42M
Submitted services
3,942,610
Denial rate
5.3%
Allowed / service
$7.76
Submitted charges
$70.69M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9176 billing FAQ
What is HCPCS code J9176?
J9176 is a HCPCS Level II J-code used to bill Injection, elotuzumab, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9176?
One unit of J9176 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J9176 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9176?
The Medicare Part B payment limit is $8.189 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $8.025 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9176?
2 NDCs currently map to J9176 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9176 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.